Creavo has developed diagnostic technology using magnetocardiography (MCG) to measure fluctuations in magnetic fields caused by heart activity. The first product resulting from the work will help physicians in A&E departments rule out significant heart disease in patients presenting with chest pains. This represents a considerable portion of A&E patients but existing protocols take up to 12 hours to resolve the issue which causes stress to them, and also imposes significant costs on the NHS.
Location: United Kingdom, England, Coventry
Total raised: $17.35M
Investors 1
| Date | Name | Website |
| - | Parkwalk A... | parkwalkad... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 03.07.2017 | - | $17.35M | - |
Mentions in press and media 4
| Date | Title | Description |
| 03.07.2017 | Creavo Medical Technologies Ltd - Closes £13.4m ($17m) funding round | Creavo Medical Technologies, the UK-based med-tech company, has announced that it has raised a further £13.4m ($17m) in equity funding. The round was oversubscribed and exceeded Creavo’s funding target, reflecting strong investor support ... |
| - | Creavo Medical Technologies – Parkwalk closes investment | We are pleased to announce that the Parkwalk Opportunities Fund has made an investment in Creavo Medical Technologies, a University of Leeds Spin-out company, as part of a £13.4 million fundraising. |
| - | Parkwalk H1 2017 update | It has been a busy first half of the year at Parkwalk. Our proprietary access to deal-flow has enabled us to deploy £46.5m in the last 12 months. Deal-flow has been enhanced by our tie-up with IP Group plc, who recently raised a further £20... |
| - | EIS: more than financial returns | As institutional investors increasingly regard ESG as an important element of their investment decision, Tom Hopkins, of Parkwalk, wonders whether this element of EIS investment should form part of the client conversation. |